Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Availability:

  • Sort by:
  • Browse by:
<< first | < prev page: of 2 records per page: next > | last >>
pages: 1 2 presentations: 1 to 50 of 87 from CROI 2018
MONDAY PLENARY SESSION
THE EARLY DAYS OF AIDS: LOOKING BACK AND THINKING AHEAD   (ABSTRACT 12)
Harold W. Jaffe
Centers for Disease Control and Prevention, Atlanta, GA, USA
from CROI 2018 on March 5, 2018 8:30 AM-9:30 AM
MONDAY PLENARY SESSION
PATHOGENESIS OF TUBERCULOSIS AND VACCINE PREVENTION   (ABSTRACT 13)
JoAnne L Flynn
University of Pittsburgh, Pittsburgh, PA, USA
from CROI 2018 on March 5, 2018 8:30 AM-9:30 AM
ORAL ABSTRACT: ADVANCES IN TB AND CRYPTOCOCCAL MENINGITIS TREATMENT AND PREVENTION
EFFECT OF TB SCREENING AND RETENTION INTERVENTIONS ON EARLY ART MORTALITY IN BOTSWANA   (ABSTRACT 31)
Andrew Francis Auld
U.S. Centers for Disease Control and Prevention (CDC), Dulles, VA, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: ADVANCES IN TB AND CRYPTOCOCCAL MENINGITIS TREATMENT AND PREVENTION
A CLUSTER-RANDOMIZED TRIAL OF SYMPTOM VS TST SCREENING TO IMPROVE CHILD IPT UPTAKE   (ABSTRACT 32)
Nicole Salazar-Austin
Johns Hopkins University School of Medicine, Baltimore, MD, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: ADVANCES IN TB AND CRYPTOCOCCAL MENINGITIS TREATMENT AND PREVENTION
SAFETY AND EFFICACY OF DOLUTEGRAVIR-BASED ART IN TB/HIV COINFECTED ADULTS AT WEEK 24   (ABSTRACT 33)
Kelly Dooley
Johns Hopkins University, Baltimore, MD, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: ADVANCES IN TB AND CRYPTOCOCCAL MENINGITIS TREATMENT AND PREVENTION
PHARMACOKINETICS OF BICTEGRAVIR ADMINISTERED TWICE DAILY IN COMBINATION WITH RIFAMPIN   (ABSTRACT 34)
Joseph M. Custodio
Gilead Science, Foster city, CA, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: ADVANCES IN TB AND CRYPTOCOCCAL MENINGITIS TREATMENT AND PREVENTION
HIGHER HIGH DOSE FLUCONAZOLE FOR THE TREATMENT OF CRYPTOCOCCAL MENINGITIS   (ABSTRACT 35)
Wadzanai Samaneka
Parirenyatwa Clinical Research Site, Harare, Zimbabwe
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: ADVANCES IN TB AND CRYPTOCOCCAL MENINGITIS TREATMENT AND PREVENTION
ADJUNCTIVE SERTRALINE IN HIV-ASSOCIATED CRYPTOCOCCAL MENINGITIS   (ABSTRACT 36)
Joshua Rhein
University of Minnesota, Minneapolis, MN, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: ADVANCES IN TB AND CRYPTOCOCCAL MENINGITIS TREATMENT AND PREVENTION
ONE MONTH OF RIFAPENTINE/ISONIAZID TO PREVENT TB IN PEOPLE WITH HIV: BRIEF-TB/A5279   (ABSTRACT 37LB)
Richard E. Chaisson
Johns Hopkins University, Baltimore, MD, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: ADVANCES IN TB AND CRYPTOCOCCAL MENINGITIS TREATMENT AND PREVENTION
URINE-BASED SCREENING FOR TUBERCULOSIS: A RANDOMIZED TRIAL IN HIV-POSITIVE INPATIENTS   (ABSTRACT 38LB)
Ankur Gupta-Wright
London School of Hygiene & Tropical Medicine, London, United Kingdom
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: ADVANCES IN TB AND CRYPTOCOCCAL MENINGITIS TREATMENT AND PREVENTION
A RANDOMIZED CONTROLLED TRIAL OF HIGH-DOSE RIFAMPIN FOR PULMONARY TUBERCULOSIS   (ABSTRACT 39LB)
Gustavo E Velásquez
Brigham and Women's Hospital, Boston, MA, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: ART: NEW DATA AND NEW INSIGHTS
SWITCH TO BICTEGRAVIR/F/TAF FROM DTG AND ABC/3TC   (ABSTRACT 22)
Jean-Michel Molina
Hôpital Saint-Louis, Paris, France
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: ART: NEW DATA AND NEW INSIGHTS
IMPACT OF RALTEGRAVIR INTENSIFICATION OF FIRST-LINE ART ON IRIS IN THE REALITY TRIAL   (ABSTRACT 23)
Diana Gibb
MRC Clinical Trials Unit at UCL, London, United Kingdom
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: ART: NEW DATA AND NEW INSIGHTS
HAIR ANTIRETROVIRAL LEVELS STRONGLY PREDICT VIROLOGIC OUTCOMES IN ACTG'S A5257 TRIAL   (ABSTRACT 24)
Monica Gandhi
University of California San Francisco, San Francisco, CA, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: ART: NEW DATA AND NEW INSIGHTS
TENOFOVIR DIPHOSPHATE IN DRIED BLOOD SPOTS IS A STRONG PREDICTOR OF VIRAL SUPPRESSION   (ABSTRACT 25)
Jose R Castillo-Mancilla
University of Colorado, Denver, Aurora, CO, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: ART: NEW DATA AND NEW INSIGHTS
MULTIPLE DAILY DOSES OF MK-8591 AS LOW AS 0.25 MG ARE EXPECTED TO SUPPRESS HIV   (ABSTRACT 26)
Randolph P Matthews
Merck Research Laboratories, North Wales, PA, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: ART: NEW DATA AND NEW INSIGHTS
COMPARATIVE LYMPHOID TISSUE PHARMACOKINETICS (PK) OF INTEGRASE INHIBITORS (INSTI)   (ABSTRACT 27)
Courtney V. Fletcher
University of Nebraska Medical Center, Omaha, NE, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: ART: NEW DATA AND NEW INSIGHTS
RIFAMPIN EFFECT ON TENOFOVIR ALAFENAMIDE (TAF) PLASMA/INTRACELLULAR PHARMACOKINETICS   (ABSTRACT 28LB)
Maddalena Cerrone
St Stephen's Clinical Research, Chelsea and Westminster Hospital, London, UK, LONDON, United Kingdom
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: ART: NEW DATA AND NEW INSIGHTS
SYSTEMATIC VS TEST-GUIDED TUBERCULOSIS TREATMENT: DATA OF THE STATIS RANDOMIZED TRIAL   (ABSTRACT 29LB)
François-Xavier Blanc
l'institut du thorax, INSERM, CNRS, UNIV Nantes, CHU Nantes, Nantes, France
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: ART: NEW DATA AND NEW INSIGHTS
RESULTS OF ACTG A5288: A STRATEGY STUDY IN RLS FOR 3RD-LINE ART CANDIDATES   (ABSTRACT 30LB)
Beatriz Grinsztejn
Fiocruz, Rio de Janeiro, Brasil, Brazil
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: ART: NEW DATA AND NEW INSIGHTS
QUESTIONS AND ANSWERS
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: SURVEILLANCE AND EPIDEMIOLOGY: NEW APPROACHES
RAPIDLY GROWING HIV TRANSMISSION CLUSTERS IN THE UNITED STATES, 2013–2016   (ABSTRACT 40)
Anne Marie France
Centers for Disease Control and Prevention, Atlanta, GA, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: SURVEILLANCE AND EPIDEMIOLOGY: NEW APPROACHES
CLUSTER ANALYSIS REVEALS IMPORTANT SHIFT OF DRIVERS OF THE HIV EPIDEMIC IN SWISS MSM   (ABSTRACT 41)
Nadine Bachmann
University Hospital Zurich, Zurich, Switzerland
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: SURVEILLANCE AND EPIDEMIOLOGY: NEW APPROACHES
PHYLOGENETIC PATTERNS OF HIV TRANSMISSION AMONG TRANSGENDER WOMEN IN LOS ANGELES   (ABSTRACT 42)
Manon Ragonnet-Cronin
University of California, San Diego, San Diego, CA, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: SURVEILLANCE AND EPIDEMIOLOGY: NEW APPROACHES
ASSESSING THE ROLE OF GEOGRAPHICAL HIV HOT-SPOTS IN THE SPREAD OF THE EPIDEMIC   (ABSTRACT 43)
Diego F Cuadros
University of Cincinnati, Cincinnati, OH, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: SURVEILLANCE AND EPIDEMIOLOGY: NEW APPROACHES
USING SUCCESSIVE SURVEYS TO CALCULATE INCIDENCE AMONG AT-RISK POPULATIONS IN THE US   (ABSTRACT 44)
Janet Chuyun Burnett
Centers for Disease Control and Prevention, Atlanta, GA, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: SURVEILLANCE AND EPIDEMIOLOGY: NEW APPROACHES
FEMALE HIV ACQUISITION PER SEX ACT IS ELEVATED IN LATE PREGNANCY AND POSTPARTUM   (ABSTRACT 45)
Renee Heffron
University of Washington, Seattle, WA, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: SURVEILLANCE AND EPIDEMIOLOGY: NEW APPROACHES
SHARP DECLINE IN MALE HIV INCIDENCE IN A RURAL SOUTH AFRICAN POPULATION (2004–2015)   (ABSTRACT 46)
Alain Vandormael
University of KwaZulu-Natal, South Africa, Durban, KZN, South Africa
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: SURVEILLANCE AND EPIDEMIOLOGY: NEW APPROACHES
ONGOING HIV MICROEPIDEMICS IN RURAL SOUTH AFRICA: THE NEED FOR FLEXIBLE INTERVENTIONS   (ABSTRACT 47LB)
Cordelia Coltart
University College London, London, United Kingdom
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: VIRUS AND HOST DETERMINANTS OF HIV/SIV PATHOGENESIS
IDENTIFICATION OF A NOVEL LOCUS OF HIV REGULATION IN POPULATIONS OF AFRICAN DESCENT   (ABSTRACT 14)
Paul J McLaren
Public Health Agency of Canada, WInnipeg, Canada
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: VIRUS AND HOST DETERMINANTS OF HIV/SIV PATHOGENESIS
HOST FACTORS ASSOCIATED WITH BNAB DEVELOPMENT IN HIV-1 CONTROLLERS   (ABSTRACT 15)
Enrique Martin-Gayo
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: VIRUS AND HOST DETERMINANTS OF HIV/SIV PATHOGENESIS
INTERDOMAIN STABILIZATION IMPAIRS CD4 BINDING AND IMPROVES IMMUNOGENICITY OF SOSIPS   (ABSTRACT 16LB)
Peng Zhang
NIH, Bethesda, MD, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: VIRUS AND HOST DETERMINANTS OF HIV/SIV PATHOGENESIS
EQUAL DISTRIBUTION OF SIV DNA IN MEMORY T HELPER CELL SUBSETS OF RHESUS MACAQUES   (ABSTRACT 17)
Stephen Lai
NIH, Bethesda, MD, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: VIRUS AND HOST DETERMINANTS OF HIV/SIV PATHOGENESIS
KINETICS OF GASTROINTESTINAL DYSFUNCTION IN ACUTE SIV INFECTION OF MACAQUES   (ABSTRACT 18)
Tiffany Hensley-McBain
University of Washington, Seattle, WA, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: VIRUS AND HOST DETERMINANTS OF HIV/SIV PATHOGENESIS
PROGRESSIVE LYMPH NODE DYSFUNCTION DURING SIV INFECTION IS NOT REVERSED WITH ART   (ABSTRACT 19)
Claire Deleage
NIH, Frederick National Laboratory for Cancer Research, Frederick, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: VIRUS AND HOST DETERMINANTS OF HIV/SIV PATHOGENESIS
P38 MAPK IN VIVO INHIBITION IMPACTS SIV-MEDIATED IMMUNE ACTIVATION & CD4 T-CELL LOSS   (ABSTRACT 20)
Anna Aldovini
Boston Children's Hospital, Boston, MA, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: VIRUS AND HOST DETERMINANTS OF HIV/SIV PATHOGENESIS
INTRON−CONTAINING HIV−1 RNA ACTIVATES TYPE I INTERFERON AND INFLAMMATORY CYTOKINES   (ABSTRACT 21)
Sean McCauley
University of Massachusetts Medical School, Worcester, MA, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
THEMED DISCUSSION: CLINICAL PHARMACOLOGY OF HIV-TB COINFECTION
DRUG-DRUG INTERACTIONS IN HIV-ASSOCIATED TB: BALANCING EVIDENCE, RISK, AND PRAGMATISM   (ABSTRACT 1159)
Gary Maartens
University of Cape Town, Cape Town , South Africa
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: CLINICAL PHARMACOLOGY OF HIV-TB COINFECTION
EFAVIRENZ PHARMACOKINETICS IN HIV/TB COINFECTED PERSONS RECEIVING RIFAPENTINE   (ABSTRACT 455)
Anthony Podany
University of Nebraska, Omaha, NE, USA
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: CLINICAL PHARMACOLOGY OF HIV-TB COINFECTION
EFAVIRENZ PHARMACOKINETICS WITH RIFAMPIN DOUBLE DOSE IN TB-HIV INFECTED PATIENTS   (ABSTRACT 456)
Daniel Warren Atwine
MSF-Epicentre, Mbarara, Uganda
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: CLINICAL PHARMACOLOGY OF HIV-TB COINFECTION
PHARMACOKINETICS OF EFAVIRENZ 400MG WITH ISONIAZID/RIFAMPICIN IN PEOPLE WITH HIV   (ABSTRACT 457)
Maddalena Cerrone
St Stephen's Clinical Research, Chelsea and Westminster Hospital, London, UK, LONDON, United Kingdom
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: CLINICAL PHARMACOLOGY OF HIV-TB COINFECTION
IN SILICO DRUG INTERACTION OF LONG-ACTING RILPIVIRINE AND CABOTEGRAVIR WITH RIFAMPIN   (ABSTRACT 458)
Rajith Kumar Reddy Rajoli
University of Liverpool, Liverpool, Merseyside, United Kingdom
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: CLINICAL PHARMACOLOGY OF HIV-TB COINFECTION
QUESTIONS AND ANSWERS
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: EARLY EVENTS: METHODS AND MECHANISMS
THEMED DISCUSSION MODERATOR
Viviana A. Simon
Icahn School of Medicine at Mt Sinai, New York, NY, USA
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: EARLY EVENTS: METHODS AND MECHANISMS
NEF UPREGULATES FASL EARLY WHILE MHCS ARE DOWNREGULATED LATE IN HIV-INFECTED CELLS   (ABSTRACT 186)
Rodrigo Matus-Nicodemos
Vaccine Research Center, NIAID, NIH, Bethesda, USA
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: EARLY EVENTS: METHODS AND MECHANISMS
HIV-1 CORE MORPHOLOGY ASSESSMENT USING SINGLE VIRION IMAGING BASED ON FRET   (ABSTRACT 185)
Anamaria Daniela Sarca
Kyoto University, Kyoto, Kyoto, Japan
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: EARLY EVENTS: METHODS AND MECHANISMS
VISUALISATION OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 CDNA BY CLICK CHEMISTRY   (ABSTRACT 187)
Frauke Christ
Katholieke University Leuven, Leuven, Belgium
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: EARLY EVENTS: METHODS AND MECHANISMS
UBP43 (USP18) ABROGATES INTERFERON AND SAMHD1-MEDIATED RESTRICTION OF HIV-1   (ABSTRACT 189)
Edmund Osei-Kuffour
Heinrich-Heine-University Hospital, Düsseldorf, Germany
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: EARLY EVENTS: METHODS AND MECHANISMS
VPR ENHANCES VIRAL GENE EXPRESSION FROM UNINTEGRATED DNA IN A DCAF1-DEPENDENT MANNER   (ABSTRACT 190)
Sarah B Nodder
Boston University, Boston, MA, USA
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: EARLY EVENTS: METHODS AND MECHANISMS
QUESTIONS AND ANSWERS
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
<< first | < prev page: of 2 records per page: next > | last >>
pages: 1 2 presentations: 1 to 50 of 87 from CROI 2018